IDEAYA Biosciences Inc., a precision medicine oncology company, has announced that data from its Phase 2 clinical trial of neoadjuvant darovasertib in primary uveal melanoma will be presented at the 2025 European Society of Medical Oncology (ESMO) meeting, scheduled for October 17-21 in Berlin, Germany. The presentation will cover preliminary results from over 90 patients across both plaque brachytherapy and enucleation-eligible cohorts. Darovasertib has received U.S. FDA Breakthrough Therapy Designation for this indication, and the company has commenced a global Phase 3 neoadjuvant registrational trial in primary uveal melanoma, known as OptimUM-10, in the third quarter of 2025. Dr. Marcus Butler from the Princess Margaret Cancer Center at the University of Toronto will present the findings. Further details from the abstract will be disclosed at a later date.